(Q37543906)

English

Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria

scientific article published on 07 July 2009

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1 reference

Europe PubMed Central

Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Gram-negative bacteria

0 references

5

object named as

Thomas J Walsh

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

author name string

Brad Moriyama

1

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Stacey A Henning

2

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Melinda M Neuhauser

3

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Robert L Danner

4

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

language of work or name

0 references

publication date

7 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Annals of Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

43

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1324-1337

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

The current state of multidrug-resistant gram-negative bacilli in North America

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Continuous infusion of beta-lactams.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Continuous infusion of ceftazidime in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Continuous beta-lactam antibiotic therapy in a double-lung transplanted patient with a multidrug-resistant Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Clinical pharmacokinetics during continuous haemofiltration

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

A primer on continuous renal replacement therapy for critically ill patients

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of continuous renal replacement therapy

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Drug dosing in continuous renal replacement therapy: general rules

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

The first international consensus conference on continuous renal replacement therapy

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of sulbactam in humans

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of cefepime in subjects with renal insufficiency

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of ceftazidime in normal and uremic subjects

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

"Comparably Massive" Penicillin G Therapy in Renal Failure

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Elimination of ampicillin and gentamicin by hemofiltration

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration.

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH)

1 reference

https://api.crossref.org/works/10.1345%2FAPH.1L638

21 January 2018

Identifiers

10.1345/APH.1L638

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37543906&oldid=2103144146"